Skip Navigation
MUSC mobile menu

Timely care key to improving survival in head and neck cancer cases

HCC researchers uncover clues to better outcomes and pinpoint health disparity issues

Evan Graboyes, M.D.
Surgeon Evan Graboyes wants his patients to continue to do well even after surgery. It's one reason his research focuses on the impact of how patients and physicians time follow-up care since that can change outcomes. Photo by Emma Vought
Celia Spell | brazell@musc.edu | November 6, 2018

Delayed care is a critically important factor in the survival of patients with head and neck cancer, and the patients who most often experience these delays are African American, according to two new studies at Hollings Cancer Center at the Medical University of South Carolina (MUSC).

These findings are reported in an article published online October 18 and by a systemic review published online October 11– both in JAMA Otolaryngology - Head & Neck Surgery. MUSC Hollings Cancer Center researcher and lead author Evan Graboyes, M.D., said this is a critical area of research.

"Just as some scientists work to understand cancer genetics or tumor biology in the hope of finding targets that can be modified with a new drug, we see care delivery pathways in the same light. Even just changing a few things can result in a higher survival rate of patients and decreased racial disparities in care around the country," said Graboyes, who is an MUSC Health otolaryngologist-head and neck surgeon.

Head and neck squamous cell carcinoma (HNSCC) affects the areas around the throat, voice box, nose, sinuses and mouth. The disease begins when healthy cells in the head and neck start to grow rapidly and out of control to form a tumor, according to the American Society of Clinical Oncology. Squamous cell carcinoma refers to the origin of the tumor: flat cells that form the lining of both the mouth and the throat.

While HNSCC is considered rare, making up to 4 percent of all cancer cases each year, it has a high mortality rate. The American Cancer Society estimates that almost 14,000 patients will die from this disease in the U.S. in 2018. African-Americans are at a higher risk than the general population.

Treatment for HNSCC varies depending on the stage at which the patient presents, but best practices have been tested and agreed upon by a team of doctors from across the United States. These findings, which form the basis for the National Comprehensive Cancer Network (NCCN) guidelines for treating this form of cancer, shaped the parameters of these two studies.

According to the NCCN guidelines for treatment, patients undergoing surgery for HNSCC need to receive postoperative radiotherapy (PORT) within six weeks of their surgical procedure to maximize their chances of a cure.

Graboyes’ study found that delays starting PORT are common and occurred in 45 percent of the patients involved in his research. While examining these findings, the team also determined that 56 percent of African American patients received delayed care while only 43 percent of white patients did.

Graboyes and his team investigated the processes of care that caused delays and found many factors contribute. Patients who received their pathology report within seven days of surgery were four times more likely to follow treatment guidelines by starting PORT within six weeks.

Patients who had care in two different hospitals rather than continuous care at one hospital or academic medical center were more likely to experience delays as well. Those who met with radiation oncologists before surgery had an 8.9-fold increase in timely PORT.

“We know that African-American with this disease have a significantly higher rate of mortality than white patients, but we aren’t sure why,” Graboyes said. “This research showed us that delays in treatment disproportionately affected African-American, which could be one of the factors contributing to their lower survival rates.”

More research is still needed to determine the specific barriers to timely and equitable HNSCC care, and racial differences as well as treatment delays in other aspects of cancer care continue.

Barriers to cancer treatment in general often relate to a patient’s insurance status, the cost of the procedure, fear or distrust of the medical system, lack of knowledge of the disease and a lack of perceived importance.

Graboyes aims to enact real change that will benefit future patients in South Carolina and across the country. “We hope that these data will be helpful for head and neck cancer providers and health care policy makers to understand the magnitude of the problem and spur coordinated action to address its root causes,” he said.

“We can’t always control the inner workings of a disease. But we can change the way in which cancer care is delivered to patients, and that’s exciting to me.”


(Research on this topic by Evan M.Graboyes, M.D., is supported by a grant from the National Cancer Institute and Hollings Cancer Center.)

 


Hollings awards funding to encourage innovative research (MUSC News, May 7, 2018)

MUSC and SCSU team up to tackle health disparities (MUSC News, Oct. 27, 2017)

Scientific retreat tackles tough issues of health disparities, racism (MUSC News, Nov. 18, 2015)

Fighting health disparities with grants, students and the public (MUSC News, Sept, 28, 2015)


More Hollings Cancer Center News

Subscribe to our newsletters

Suggest a story



 

 

View MUSC's Facebook page Follow MUSC on Twitter View the MUSC Health Youtube channel Read the MUSC Health blog circle arrow MUSC_TAG_SOLID_1C